Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 14/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TOP1 | P11387 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18999192 | 0.88 | NQO2 (0.40) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL17469791 | 0.84 | WDR5 (0.49) | NQO2HPGDTDP1WDR5KIT | |
| SCHEMBL17469784 | 0.82 | ATR (0.47) | NQO2ALDH1A1HPGDHSD17B10WDR5 | |
| SCHEMBL17469787 | 0.81 | WDR5 (0.45) | NQO2PRMT1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL17469786 | 0.81 | WDR5 (0.41) | NQO2PRMT1ALDH1A1HPGDHSD17B10 | |
| Furamidine SCHEMBL549198 | 0.73 | NQO2 (1.00) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL17469775 | 0.72 | F2 (0.49) | KITFLT3NTRK3 | |
| SCHEMBL4357250 | 0.72 | NQO2 (0.96) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| Furamidine SCHEMBL7734063 | 0.72 | TOP2A (1.00) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| Furamidine SCHEMBL31175984 | 0.72 | TOP2A (1.00) | NQO2PRMT1ALDH1A1TOP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | NQO2 51/4885PRMT1 2331/4885ALDH1A1 635/4885 |
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | NQO2 51/4885PRMT1 2331/4885ALDH1A1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.